Lactobacillus gasseri K9: genomic and in vitro characterization of vaginal probiotic potential
Genomic and in vitro analysis of a vaginal L. gasseri strain shows absence of virulence and antibiotic resistance genes alongside favorable preclinical functional traits — no human clinical efficacy data exist.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Absence of virulence genes | D | ▲ Favorable | qualitative: not detected by VFDB (no numeric effect size) | 1 |
| Absence of antibiotic resistance determinants | D | ▲ Favorable | qualitative: not detected by CARD and ResFinder (no numeric effect size) | 1 |
| Adhesion and biofilm formation traits in vitro | D | ▲ Favorable | qualitative: presence of adhesion genes confirmed; in vitro assays positive (no IC reported) | 1 |
| Tolerance to simulated gastrointestinal stress | D | ▲ Favorable | qualitative: survival reported in simulated conditions (no numeric IC) | 1 |
| Pathogen inhibition in vitro | D | ▲ Favorable | qualitative: inhibition zones reported (no numeric IC or effect size) | 1 |
| Safety: absence of hemolysis and mucin degradation | D | ▲ Favorable | qualitative: negative results in hemolysis and mucin degradation assays (no numeric IC) | 1 |
| Unique genomic sequences in pangenome (12 sequences exclusive to K9/Q9001) | D | — Insufficient | descriptive: 12 unique sequences identified vs 278 genomes; functional relevance unknown | 1 |
Context
Lactobacillus-dominated vaginal microbiota is associated with protection against infections. L. gasseri is a frequent vaginal commensal classified as GRAS by the FDA. Identifying strains with verified safety profiles and probiotic traits is a necessary step before any formulation development.
What the study showed
The 1,872,894 bp genome with 1,779 genes and 34.83% GC content revealed no virulence genes (VFDB) and no antibiotic resistance determinants (CARD, ResFinder). Functional annotations identified genes for adhesion, carbohydrate metabolism, and secondary metabolite biosynthesis. Pangenome analysis across 278 genomes identified 12 sequences unique to K9 and Q9001, mostly encoding hypothetical proteins. No numeric clinical effect sizes were reported; all outcomes are in vitro or genomic.
How it was done
In vitro and genomic single-strain study. Complete genome sequencing with annotation via multiple platforms (RAST, KEGG, COG, CAZyme, BAGEL4, AntiSMASH). Phenotypic assays included simulated acid and bile tolerance, adhesion, auto-aggregation, biofilm formation, hemolysis, mucin degradation, and pathogen inhibition. No clinical control group, human participants, or temporal follow-up.
Effect magnitude
No calculable clinical effect size. Data are qualitative (gene presence/absence) or semi-quantitative in vitro without reported 95% CI.
Limitations
Exclusively preclinical study (in vitro + genomic); no animal models, human epithelial cells, or clinical trials. No formal risk-of-bias tool applied (RoB 2, ROBINS-I, AMSTAR-2), as this is a descriptive single-strain study. Inferred genomic traits do not equal demonstrated in vivo function. Absence of resistance genes detected by CARD/ResFinder does not exclude phenotypic resistance.
In clinical practice
No clinical recommendation is supported by this study. Practitioners must not extrapolate in vitro results to patient efficacy or safety. The study is relevant only as characterization of a candidate for future development.
What is still missing
Studies in vaginal epithelial models, animal experiments, and subsequently RCTs in women with bacterial vaginosis or recurrent candidiasis are needed to establish clinical efficacy and safety.